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Abstract—Inducible NO synthase (iNOS) is expressed by macrophages and smooth muscle cells in atherosclerotic lesions.
Previously, we have established a mouse model for vein graft arteriosclerosis by grafting autologous jugular veins or
vena cava to carotid arteries. Using this model, we studied the role of iNOS in the development of vein graft
arteriosclerosis in iNOS
/ mice. Four weeks after grafting, neointimal hyperplasia of vein grafts in iNOS
/ mice was
increased 2-fold compared with that of wild-type controls. Neointimal lesions contained mainly MAC-1
 macrophages
and -actin
 smooth muscle cells (SMCs) in both vein grafts of iNOS
/ and iNOS
/ mice. Immunofluorescence
analysis revealed that increased iNOS expression in neointimal macrophages and SMCs of wild-type, but not iNOS
/,
mice coincided with increased vascular endothelial growth factor (VEGF) expression in vein grafts. When vein grafts
were performed in iNOS
//TIE2-LacZ transgenic mice expressing LacZ gene only in endothelial cells, the number of
-galactosidase
 cells in iNOS
/ vein grafts were significantly decreased. Furthermore, treatment with the NOS
inhibitor N
G-nitro-L-arginine methyl ester resulted in delayed endothelial progenitor cell attachment, whereas L-arginine
intake through drinking water enhanced endothelial repair. Interestingly, local application of VEGF to iNOS
/ vein
grafts restored endothelial progenitor homing and reduced neointimal lesions, whereas the VEGF receptor inhibitor
SU1498 increased the lesion formation. Additionally, iNOS-deficient SMCs showed a low level of VEGF production
in response to interleukin 1 stimulation. Thus, iNOS deficiency accelerates neointima formation by abrogating VEGF
production and endothelial progenitor cell attachment and differentiation. (Circ Res. 2006;98:412-420.)
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utologous vein grafts are a common clinical procedure
for vascular reconstruction, but their patency rate is
limited by obliterative stenosis because of proliferative thick-
ening of the intima. Neointimal hyperplasia develops rapidly
once veins are subject to arterial blood pressure.1 A hallmark
of lesion initiation is endothelial cell damage, which occurs
within the first week after surgery.2 Previously, we estab-
lished a mouse model of vein graft arteriosclerosis that
resembles certain characteristics of human vein graft disease.3
We demonstrated that 1 of the earliest events after grafting
was vascular cell apoptosis followed by endothelial progen-
itor cell repair.4,5 Venous endothelial cells became apoptosis
in the arterial circulation and were replaced by circulating
endothelial progenitors, which reached confluence within 4
weeks and differentiated into mature endothelial cells.5 Thus,
the balance between apoptosis and progenitor cell repair
could be crucial in determining lesion development in vein
grafts.
NO is thought to be a key regulator in the development of
atherosclerosis.6–9 Classical cardiovascular risk factors, such
as hypertension, diabetes mellitus, hypercholesterolemia, and
smoking all impair NO function. NO is formed from
L-arginine by the enzyme NO synthase (NOS). Three distinct
isoenzymes of NOS are known to exist: constitutive-type
isoforms, such as neuronal NOS (nNOS) and endothelial cell
NOS (eNOS), and the inducible type of the enzyme (iNOS).
The latter is widely distributed in a variety of cell types,
including SMCs and leukocytes, responds to a variety of
stimuli, and can produce a very high output of NO.10 NO is a
pleiotropic signaling molecule involved in numerous process-
es,11 including lipid oxidation, mononuclear cell infiltration,
and SMC homeostasis.12–16 Notably, eNOS is essential for the
survival, migration, and angiogenic response of mature en-
dothelial cells and has recently been implicated in endothelial
progenitor cell mobilization.17 However, it remains to be
clarified whether iNOS might be important for endothelial
progenitor cell recruitment to sites of injury.
To elucidate the role of iNOS in vascular graft-induced
neointima formation, we performed vein bypass grafts in
iNOS
/ and iNOS
/ mice and compared neointimal lesions
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4124 and 8 weeks after surgery. We investigated whether altered
progenitor cell repair in iNOS-null mice contributed to
neointima formation in vivo and studied the molecular
mechanism by comparing VEGF expression in vivo and in
vitro.
Materials and Methods
Mice
All animal experiments were performed according to protocols
approved by the Institutional Committee for Use and Care of
Laboratory Animals. iNOS
/ mice were purchased from The
Jackson Laboratory (Bar Harbor, Maine) and used as breeders. The
mice were maintained on a light/dark (12/12 hour) cycle at 22°C
receiving food and water ad libitum.
Three genotypes of iNOS
/, iNOS
/, and iNOS
/ mice were
identified using the PCR protocol of The Jackson Laboratory,
with a slight modification. Briefly, genomic DNA was isolated
from tail tissues by enzyme digestion and precipitation. DNA (50
ng) in reaction buffer was thermocycled with 0.4 mol/L of each
primer (0IMR1216: 5-ACA TGC AGA ATG AGT ACC GG-3;
0IMR1217: 5-TCA ACA TCT CCT GGT GGA AC-3; and
OIMR1218: 5-AAT ATG CGA AGT GGA CCT CG-3)a t
optimal temperature and separated by electrophoresis on agarose
gels producing a single 108 and 270 bp band in iNOS
/ and
iNOS
/ mice, respectively, whereas both bands were visible in
iNOS
/ mice.
TIE2-LacZ mice18 expressing -galactosidase (gal) under the
control of the endothelial-specific protein TIE2 promoter were
purchased from The Jackson Laboratory. -Gal activity of cells from
mice is mainly localized in the nucleus. Three genotypes of LacZ
/,
LacZ
/, and LacZ
/ mice were identified using the PCR protocol
of The Jackson Laboratory (primers: 5-ATC CTC TGC ATG GTC
AGG TC-3 and 5-CGT GGC CTG ATT CAT TCC-3). iNOS
/
mice were crossed with TIE2-LacZ mice in our laboratory, and
heterozygous offspring were mated to produce iNOS-deficient mice
expressing -gal in endothelial cells (TIE2-LacZ/iNOS
/).
Vein Graft Procedure and Treatment
For vein grafts, animals of the same genotype as donors and
recipients were used. The procedure was similar to that described
previously.3 Briefly, the vena cava from 3-month-old mice was
harvested. The right common carotid artery was mobilized free from
the bifurcation at the distal end toward the proximal, cut in the
middle, and a cuff placed at the end. The cuff was made of an
autoclavable nylon tube 0.63 mm in diameter outside and 0.5 mm
inside (Portex Ltd, Hythe-Kent, UK). The vein segment was grafted
between the 2 ends of the carotid artery by sleeving the ends of the
vein over the artery cuff and ligating them together with the 8-0
suture. Immediately after vessel grafting, SU1498 (10 mol/L;
Calbiochem-EMD Biosciences) or vascular endothelial growth fac-
tor (VEGF)-165 (100 ng/mL; Sigma) was applied to the adventitia
dissolved in a 20% pluronic-127 gel (pH 7.2) as described previous-
ly.19,20 On contact with the tissues, the solutions gelled immediately,
generating a translucent layer that enveloped the grafted vessel
segment. In addition, 2 groups of mice received either N
G-nitro-L-
arginine methyl ester (L-NAME) (1 g/L) or L-arginine (25 g/L;
Sigma) in their drinking water, a dose previously shown to reduce
lesion formation in animal models.21 Supplementation was started 3
Figure 1. Neointima formation in iNOS/
and iNOS/ vein grafts. Mouse vena
cava was isografted into carotid arteries
and harvested 0, 4, or 8 weeks after sur-
gery. Vein grafts of iNOS/ (a, c, e) and
iNOS/ (b, d, f) were sectioned and
stained with hematoxylin/eosin. The
lesion area was measured microscopi-
cally. Data in g represent mean values
(SD) of the neointimal area obtained
from 8 animals per group, respectively.
*Signiﬁcant difference between iNOS/
and iNOS/ mice, P0.05.
Mayr et al iNOS in Arteriosclerosis 413days before the vein graft procedure and continued until mice were
euthanized.
Histology and Lesion Quantification
For histological analysis, in vivo perfusion with 4% phosphate-
buffered formaldehyde was performed, as described previously.22
Vein grafts were harvested by cutting the implanted segments from
the native vessels at the cuff end. The grafts were dehydrated in
graded ethanol baths, cleared in xylol, embedded in paraffin, and
sectioned. Neointimal lesions were defined as the region between the
lumen and media, which contains 2 to 3 layers of condensed cells
without microvessels. For lesional area measurement, sections were
reviewed using a BX60 microscope (Zeiss) equipped with a camera
and television monitor. Images were first scanned, saved and then
overlaid by different linings to trace the lumen and media. The lesion
area was determined by subtracting the area of the lumen from the
area enclosed by the line inside of the media.
Reverse-Transcription Polymerase Chain Reaction
The procedure used for RT-PCR was similar to that described
elsewhere.23 Total RNA was prepared with absolutely RNA RT-PCR
Miniprep Kit (STRATAGENE). The following primers were used:
iNOS (5-CGA GGA GGC TGC CTG CAG ACT TGG-3 and
5-CTG GGA GGA GCT GAT GGA GTA GTA-3) and GAPDH
(5-CGG AGT CAA CGG ATT TGG TCG TAT-3 and 5-AGC
CTT CTC CAT GGT GGT GAA GAC).
Immunofluorescent Staining
For frozen section preparation, vein grafts were harvested without
perfusion and immediately frozen in liquid nitrogen. The procedure
used for immunofluorescent staining was similar to that described
previously.24 Briefly, serial 5-m thick frozen sections were labeled
with rat monoclonal antibodies against mouse MAC-1
 (CD11b/18)
leukocytes (BD Biosciences Pharmingen), CD31 (Abcam) or a
mouse monoclonal antibody against -actin conjugated with Cy3
(Sigma), and a rabbit antibody against iNOS (BD Transduction
Laboratories) or VEGF (Santa Cruz Biotechnology). The sections
were visualized with swine anti-rat Ig-Cy3 and anti-rabbit Ig
conjugated with FITC (DakoCytomation).
Immunohistochemistry
The procedure used in the present study was similar to that described
previously.3 Briefly, serial 5-m thick frozen sections were cut from
cryopreserved tissue blocks. The sections were overlayered with rat
monoclonal antibodies against mouse MAC-1
 leukocytes (CD11b/
18) or endothelial marker CD31. After washing with PBS, sections
were incubated with rabbit anti-rat Ig (DakoCytomation) for 1 hour
and developed with APARP. For SMC staining, a mouse monoclonal
antibody against -actin (Sigma) labeled with phosphatase was used.
Semiquantitive evaluation was performed at 1025 magnification.
Positive stained cells in the intima were counted on 2 regions of each
section and expressed as the percentage of total nuclei per 100 m
of the vessel wall. For CD31
 cells, staining intensity was measured
using a computer software AxioVision.
En Face Preparation and X-Gal Staining
Mice were anesthetized and perfused with 0.9% NaCl solution and
subsequently perfusion fixed with 2% formaldehyde and 0.2%
glutaraldehyde (pH 7.2) for 2 and 10 minutes, respectively. The
procedure for en face preparation is similar to that described
elsewhere.25,26 In short, vein segments were harvested and the
samples were fixed with 2% formaldehyde and 0.2% glutaraldehyde
at 4°C for 24 hours. Each vessel segment (55m m
2) was prepared
free from the adventitia and cut open. Vessel segments were
mounted with the endothelium up on a glass slide (2.67.5 cm). The
procedure for X-gal staining was similar to that described previous-
ly.27 Briefly, vein segments were incubated at 37°C for 18 hours in
PBS supplemented with 1 mg/mL X-gal (Sigma). Vessel segments
were rinsed with 3% DMSO in PBS and mounted with the endothe-
lium up on a glass slide (2.67.5 cm). Positive stained (blue) cells
were enumerated under the microscope.
Western Blot Analysis
Preparation of extracts from whole vessel wall for Western blotting
was performed as described previously.28 Briefly, 20 g of protein
were separated on a 10% polyacrylamide gel, blotted, and incubated
with a rabbit polyclonal antibody to VEGF (1:100; Santa Cruz
Biotechnology) followed by a rabbit IgG secondary antibody. To
confirm equal loading, membranes were stained with antibody
against actin (Santa Cruz Biotechnology).
Cell Culture and ELISA
Vascular SMCs were isolated by collagenase digestion of the mouse
thoracic aorta and cultured in DMEM with 15% FCS at 37°C in an
atmosphere of 5% CO2 as described previously.19 Cells were used for
experiments between passage 10 and 20. On subconfluence, SMCs
were placed in DMEM medium with 0.5% FCS for 24 hours (the
presence of a low concentration of FCS is necessary to stabilize
VEGF released into the medium) and subsequently exposed to
Figure 2. RT-PCR and immunoﬂuorescence staining for iNOS in
vein grafts. a, Total RNA was extracted from 4-week vein graft
tissues. Levels of iNOS mRNA were detected by RT-PCR. b,
Double immunoﬂuorescence staining. Cryostat sections from
4-week vein grafts of iNOS/ and iNOS
/ mice were labeled
with a rat monoclonal antibody MAC-1 or mouse monoclonal
antibody against -actin conjugated with Cy3 (red ﬂuorescence)
and a polyclonal rabbit anti-iNOS antibody visualized by a swine
anti-rabbit Ig-FITC conjugate (green ﬂuorescence).
414 Circulation Research February 17, 2006interleukin (IL)-1 (20 ng/mL; R&D Systems). In some experi-
ments, exposure to IL-1 occurred in the presence of the NOS
inhibitor L-NAME (5 mmol/L) or L-arginine (10 mmol/L), respec-
tively. VEGF was measured in the conditioned medium using a
commercial ELISA kit (R&D Systems).
Statistical Analysis
Statistical analyses were performed using the Student’s t test, the
Mann–Whitney U test, or ANOVA, respectively. A probability value
of 0.05 was considered significant.
Results
Accelerated Lesions in iNOS-Deficient Mice
Before grafting, the composition of the venous wall was
similar in iNOS
/ and iNOS
/ mice (Figure 1a and 1b).
Four weeks after grafting, neointimal hyperplasia, ie, thick-
ening of the venous wall to more than 10 cell layers, was
observed in wild-type mice (Figure 1c). Notably, neointima
formation and cell density were markedly increased in vein
grafts of iNOS
/ mice (Figure 1d). At 8 weeks, a loss of cell
density was observed in both wild-type and knockout mice
(Figure 1e and 1f). Figure 1g summarizes quantitative data on
neointima thickness as measured microscopically. The lesion
area of vein grafts derived from iNOS
/ mice was approxi-
mately doubled compared with wild-type controls at 4 and 8
weeks, and total cell numbers in 4-week grafts of iNOS
/
mice were markedly higher than those of wild-type animals
(25323 versus 10816, counted over 100 m in length).
Cell Composition and iNOS Expression in
Vein Grafts
Intensive immunostaining for MAC-1
 macrophages was
observed especially in the surface area of vein grafts from
iNOS
/ mice, whereas -actin
 SMCs were found in the
deeper layers of the neointima. MAC-1
 cells were the
predominant cell type in neointimal lesions at 4 weeks (52%
versus 69%), whereas -actin positive SMCs constituted
approximately 10% of cells in lesions (11% versus 9%).
Moreover, SMCs became dominant cells in neointimal le-
sions of 8-week vein grafts in both knockout and wild-type
mice (Table I in the online data supplement available at
http://circres.ahajournals.org). No significant difference in
ratios of MAC-1
 macrophages and -actin
 cells were
observed between iNOS
/ and iNOS
/ mice, indicating that
iNOS deficiency does alter neointimal size but not cell
composition.
iNOS is known to be highly expressed in atherosclerotic
lesions,7 but its presence in neointimal lesions of vein grafts
remains to be determined. RT-PCR data presented in Figure
Figure 3. Effects of L-NAME and
L-arginine on neointimal lesions. Wild-
type mice received either L-NAME (1 g/L)
or L-arginine (25 g/L) in their drinking
water 3 days before the operation until
animals were euthanized to harvest the
vein grafts after 4 or 8 weeks. a through
f, Representative pictures of hematoxy-
lin/eosin sections, and the graph pres-
ents meansSD of the neointimal area
obtained from 8 animals per group,
respectively. *Signiﬁcant difference from
untreated controls, P0.05.
Mayr et al iNOS in Arteriosclerosis 4152a suggest increased iNOS mRNA transcription in wild-type,
but not knockout, vein grafts. Similarly, immunostaining for
iNOS was enhanced in neointimal macrophages and SMCs 4
weeks after grafting (Figure 2b) compared with freshly
harvested veins. Vein segments stained with normal rat serum
served as a negative control (data not shown). As expected,
no staining for iNOS was detectable in vein grafts of iNOS
/
mice (Figure 2b).
Role of NO in Vein Graft Arteriosclerosis
It is well established that the activity of all NOS isoforms can
be enhanced by L-arginine supplementation in the drinking
water and inhibited by administration of the nonselective
NOS inhibitor L-NAME. Whereas treatment with L-NAME
accelerated neointima formation in wild-type mice and re-
sulted in increased cell density, mainly mononuclear cells and
SMCs, compared with untreated controls (Figure 3a-d),
L-arginine supplementation reduced neointimal lesion size
and inhibited mononuclear cell infiltration (Figure 3e and 3f).
The graph in Figure 3 summarizes the data derived from 8
mice per group.
NO Influences Endothelial Progenitor Cell Homing
We demonstrated previously that endothelial cells in vein
grafts are replaced by circulating progenitor cells. Because
NO was recently implicated in endothelial progenitor cell
mobilization,17 we wanted to determine whether iNOS defi-
ciency would interfere with progenitor cell recruitment to
vein grafts. Endothelial integrity was monitored using TIE2-
LacZ/iNOS
/ mice, which express the LacZ gene in only
endothelial cells. As expected, extensive endothelial loss
occurred in wild-type vein grafts (data not shown) and
endothelial cells were regenerated in vein grafts 4 weeks after
surgery (Figure 4a). Whereas L-arginine supplementation
accelerated restoration of the endothelial monolayer after
grafting, the number of newly formed endothelial cells was
markedly reduced in iNOS
/ mice and in wild-type mice
treated with L-NAME (Figure 4a and 4b). These findings
suggest that iNOS influences endothelial progenitor cell
homing or attachment.
iNOS Influences VEGF Production
Because VEGF is a key chemokine and growth factor for
EPCs, VEGF expression in vein grafts was measured by
Western blot analysis and immunostaining. VEGF expression
peaked in vein grafts 3 days after surgery and was significant
lower in vein grafts of iNOS
/ mice compared with wild-
type controls (Figure 5a). Interestingly, microvessels were
abundant in the adventitia of vein grafts in iNOS
/ mice but
rare in iNOS
/ vein grafts (Figure 5b, top). Cells within
these microvessels were identified to be CD31
 (red) express-
ing VEGF (green) (Figure 5b, middle). Neointimal SMCs
also expressed high levels of VEGF at 4 weeks (Figure 5b,
bottom). This local VEGF expression is likely to contribute to
the recruitment of circulating endothelial progenitors to vein
graft surface. To further analyze the effects of iNOS on vasa
(microvessel) formation in vein grafts, sections of control
vessels and vein grafts were labeled with anti-endothelial
marker CD31 and quantified for both iNOS
/ and iNOS
/
mice. Data shown in Figure 6a through 6d are representative
images indicating that microvessels are mainly localized in
the adventitia, and much less in neointimal lesions. Figure 6e
summarized data of 8 animals per group indicate the signif-
icant higher in microvessel density in vein grafts derived
from wild-type mice compared with knockouts.
NO-Induced VEGF Expression Plays a Role in
Lesion Formation
Because SMCs in neointimal lesions expressed high levels of
VEGF (Figure 5b), we cultivated aortic SMCs from both
iNOS
/ and iNOS
/ mice and measured VEGF production
in response to IL-1 stimulation. Figure 7a demonstrates that
levels of VEGF in the conditioned medium of iNOS
/ SMCs
reached a maximum after 24 and 48 hours but were signifi-
cantly lower for iNOS
/ SMCs. Furthermore, IL-1–in-
duced VEGF production in iNOS
/ SMCs was inhibited by
preincubation with NOS inhibitor L-NAME, whereas
L-arginine significantly enhanced VEGF induction in
Figure 4. NO-inﬂuenced endothelial cell repair in vein grafts.
Freshly harvested vena cava segment from iNOS//TIE2-LacZ,
iNOS//TIE2-LacZ, or TIE2-LacZ mice were isografted into
carotid arteries with or without L-NAME or L-arginine treatment.
The grafts were harvested at 4 weeks and incubated with sub-
strate X-gal as described in Materials and Methods. The blue
color on en face photographs indicates -gal cells (a). Arrows
highlight examples of positive cells. The number of endothelial
cells present per 400 ﬁeld was quantiﬁed and data are given
as meansSD (n5) (b). *Signiﬁcant difference from untreated
group, P0.01.
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/, but not iNOS
/, SMCs (Figure 7b). Taken to-
gether, our results indicate that NO generated by iNOS
contributes to VEGF production in SMCs.
To further clarify the functional relevance of NO-induced
VEGF production in vivo, vein grafts were locally treated
with VEGF receptor inhibitor SU1489. As shown in Figure
8a, SU1489 treatment markedly reduced the number of
endothelial cells at 4 weeks after grafting in wild-type mice,
whereas local VEGF transfer improved endothelial repair in
iNOS
/ mice. Thus, VEGF treatment restored endothelial
progenitor homing to the surface of iNOS
/ vein grafts.
Concomitantly, neointima formation was enhanced in the
SU1489-treated group compared with untreated controls,
whereas local VEGF treatment reduced lesion formation in
iNOS
/ mice (Figure 8b). In addition, VEGF treatment
slightly increased the density of microvessels in the adventitia
(data not shown). These findings support the notion that loss
of VEGF expression may, at least partially, be responsible for
impaired endothelial progenitor cell recruitment and in-
creased neointima formation in iNOS
/ mice.
Discussion
We reported previously that 1 of the earliest cellular events in
neointima formation of vein bypass grafts is cell death,4
triggering an inflammatory response26 followed by endothe-
lial progenitor cell repair.5 In this process, circulating pro-
genitor cells are largely responsible for replacing the endo-
thelium in vein grafts.5,29 In the present study, we
demonstrate in our murine vein graft model that iNOS
deficiency accelerates neointima lesion formation by abrogat-
ing endothelial progenitor cell repair and facilitating mono-
nuclear cell infiltration and SMC accumulation. Thus, iNOS
is a crucial enzyme that attenuates lesion development in vein
grafts by stimulating endothelial progenitor cell homing and
differentiation.
Accumulating evidence indicates that endothelial progen-
itor cells in the blood have the capacity to proliferate,
migrate, and differentiate into mature endothelial cells.30–33
Previously, our group demonstrated that the number of -gal

cells was reduced at 3 days and disappeared completely by 4
weeks after grafting, when a vein fragment from a TIE2-LacZ
transgenic mouse expressing the marker gene LacZ only in
endothelial cells was isografted into the carotid artery of
wild-type mice.5 Conversely, -gal
 cells were observed on
the surface of vein segments donated by wild-type mice
isografted into TIE2-LacZ mice at 1 week and reached
confluence by 4 weeks. These data show that circulating
progenitor cells cover the surface of neointimal and arterio-
sclerotic lesions of vein grafts.34 Furthermore, other groups
have demonstrated that eNOS is essential for progenitor cell
mobilization17 and that iNOS contributes to endothelial pro-
genitor cell recruitment into ischemic tissues.35 In the present
study, we found that endothelial cell numbers on the surface
of vein grafts are significantly reduced in iNOS
/ mice and
in L-NAME–treated wild-type mice, suggesting that NO is
needed for endothelial progenitor cell attachment and
differentiation.
Another important observation is the finding that locally
produced VEGF in vein grafts is significantly reduced in
iNOS
/ mice, which is related to decreased endothelial
attachment. It has been shown that VEGF production in
SMCs could be attenuated by inhibition of NOS activity,36
indicating a relationship between these 2 factors. NO was also
shown to be involved early in angiogenesis, where inhibition
of NOS activity abolished the increase in capillary prolifer-
ation.37 NO is released from endothelium by increased shear
stress38,39 and in vivo in response to increased blood flow.40
Figure 5. Western blot analysis and immunoﬂuorescence stain-
ing for VEGF in vein grafts. a, Protein extracts from vein grafts
were probed for VEGF in Western blot analysis. Bands were
quantiﬁed by scanning and normalizing for actin. b, Double im-
munoﬂuorescence staining. Cryostat sections from 4-week vein
grafts of iNOS/ and iNOS
/ mice were labeled with a rat
monoclonal antibody CD31 or mouse monoclonal antibody
against -actin conjugated with Cy3 (red ﬂuorescence) and a
polyclonal rabbit anti-VEGF antibody visualized by a swine anti-
rabbit Ig-FITC conjugate (green ﬂuorescence).
Mayr et al iNOS in Arteriosclerosis 417NO and VEGF are known to be synergistic and/or comple-
mentary in other angiogenic situation.17,41 Our results dem-
onstrated that iNOS-mediated NO production is a key event
for VEGF production in SMCs stimulated by IL-1. Thus,
NO together with NO-induced VEGF may synergistically
serve as chemokines for endothelial progenitor homing and
growth factors for cell proliferation and differentiation in vein
grafts.
Because local concentration of VEGF could influence both
endothelial repair on the surface of vein grafts and angiogen-
esis or vasa formation in the vessel wall, we have therefore
compared the density of microvessels in grafts, and demon-
Figure 6. Immunohistochemical staining for CD31. Sections from freshly harvested vein (a) and 1-week (b) and 4-week (c and d) vein
grafts of iNOS/ (a, b, and d) and iNOS
/ (c) mice were labeled with a rat monoclonal antibody CD31 and visualized by alkaline
phosphatase–anti-alkaline phosphatase techniques. Dotted lines indicate the border between media and adventitia. Note abundant
vasa vasorum in the adventitia. e, Statistical data of meansSEM (n8). *Signiﬁcant difference between 2 groups, P0.05.
Figure 7. VEGF induction in aortic SMCs from iNOS/ and
iNOS/ mice. SMCs were treated with IL-1 (20 ng/mL). VEGF
was measured in the conditioned medium by ELISA at various
time points (a). *Signiﬁcant difference from iNOS/ SMCs,
P0.001. b, Inhibition of NOS activity by L-NAME (5 mmol/L)
reduces VEGF synthesis. Supplementation of L-arginine
(10 mmol/L) increases VEGF production. Values are meansSD
of 3 independent experiments, each performed in triplicate.
**Signiﬁcant difference from L-arginine–treated group, P0.01.
Figure 8. VEGF-inﬂuenced endothelial repair and neointimal
lesions in vein grafts. Vein segment from iNOS//TIE2-LacZ,
iNOS//TIE2-LacZ, or TIE2-LacZ mice were isografted into
carotid arteries with or without local SU1498 or VEGF treatment.
The grafts were harvested at 4 weeks and incubated with sub-
strate X-gal as described in Materials and Methods. The number
of endothelial cells present per 400 ﬁeld was quantiﬁed (a). In
addition, vein grafts with or without treatment were processed
for hematoxylin/eosin sections. Neointimal lesions were quanti-
ﬁed as described in Materials and Methods (b). Data are given
as meansSD (n5). *Signiﬁcant difference from untreated
group, P0.05.
418 Circulation Research February 17, 2006strated a lower level of microvessels in iNOS
/ mice (Figure
6). These results indicate iNOS could also be an important
enzyme for endothelial progenitor cell functions in terms of
vasa formation in the adventitia. Concomitantly, Ii et al35
demonstrated that iNOS produced from EPCs appears to play
a crucial role in cardioprotection, possibly via the involve-
ment in angiogenesis. Is there any relationship among endo-
thelial repair, neointimal formation, and vasa function in vein
grafts? As mentioned above, decreased microvessel density in
iNOS
/ vein grafts may directly relate to lower level of local
VEGF production that influences endothelial repair on the
surface of vein grafts. On the other hand, microvessels within
the vessel wall might be involved in transporting mononu-
clear cells and smooth muscle progenitors from the adventi-
tial side based on observations that there are some microves-
sels in the media and neointima of 4-week vein grafts.
Previously, we demonstrated that mononuclear cell recruit-
ment into neointima was significantly reduced in ICAM-1
/
mice,26 suggesting these cells are mainly derived from endo-
thelial side of the vein grafts. Thus, we hypothesize that
neointimal cells may be mainly recruited from endothelial
side of the vessel, although vasa vasorum could be involved
as well.
The role of iNOS in vascular pathology is variable, and
cholesterol levels appear to be among the factors determining
whether iNOS is pro- or antiatherosclerotic. Although iNOS
deficiency has no effect on atherosclerosis development in
apoE/iNOS-dKO mice on normal chow,42 it substantially re-
duced atherosclerosis in apoE-null mice on Western diet.14,15 In
contrast to spontaneous atherosclerosis, iNOS plays a protective
role in transplant atherosclerosis and chronic cardiac rejection is
accelerated in iNOS
/ mice.13 Similarly, our findings demon-
strate that neointima formation is enhanced in vein grafts of
iNOS-deficient mice. These observations suggest that iNOS
plays different role in hyperlipidemia-induced atherosclerosis
and vascular graft arteriosclerosis. In hyperlipidemia-induced
atherosclerosis, reduction in lesion formation was associated
with a decrease in plasma lipoperoxide concentrations.21 Hyper-
lipidemia is known to cause endothelial dysfunction, but, unlike
the vein graft model, no acute endothelial damage occurs. The
extensive loss of endothelial cells after grafting veins to arteries4
is followed by rapid progenitor cell repair.5 Therefore, different
strategies for modulating iNOS activity would be needed to treat
native atherosclerosis and vein graft stenosis.
In summary, we demonstrated that iNOS deficiency results
in exacerbated arteriosclerosis in vein grafts in a murine
model. The mechanisms of iNOS-enhanced lesion formation
involve delayed endothelial repair, ie, progenitor homing and
differentiation, in which NO-mediated VEGF production by
vascular cells is crucial. Our findings provide basic informa-
tion for developing a new strategy for treatment of vein graft
disease.
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